Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002995197 | SCV003293889 | uncertain significance | not provided | 2023-05-12 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POGZ protein function. ClinVar contains an entry for this variant (Variation ID: 2079158). This variant has not been reported in the literature in individuals affected with POGZ-related conditions. This variant is present in population databases (rs778409159, gnomAD 0.0009%). This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 1342 of the POGZ protein (p.Asn1342Lys). |
Ambry Genetics | RCV003269371 | SCV003977898 | uncertain significance | Inborn genetic diseases | 2023-05-17 | criteria provided, single submitter | clinical testing | The c.4026T>G (p.N1342K) alteration is located in exon 19 (coding exon 18) of the POGZ gene. This alteration results from a T to G substitution at nucleotide position 4026, causing the asparagine (N) at amino acid position 1342 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome- |
RCV003340581 | SCV004049777 | uncertain significance | Intellectual disability-microcephaly-strabismus-behavioral abnormalities syndrome | 2023-04-11 | criteria provided, single submitter | clinical testing |